- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05259631
Sédation par inhalation (sévoflurane) versus sédation intraveineuse (propofol) chez les adultes atteints d'une forme modérée de SDRA
Sédation par inhalation (sévoflurane) versus intraveineuse (propofol) chez les adultes atteints d'une forme modérée de SDRA : un essai pilote randomisé multicentral
The American European Consensus Conference (AECC) 1994 defined acute respiratory distress syndrome (ARDS) as an acute inflammatory syndrome manifesting as diffuse pulmonary edema and respiratory failure that cannot be explained by, but may co-exist with, left-sided heart failure. During the sequel Conference of the European Society of Intensive Care Medicine, in 2012 minor changes were made, and since that so-called Berlin definition of ARDS is used worldwide for the description of this severe disease. Three grades of severity were proposed to distinguish ARDS according to the level of hypoxemia with a mortality of 24% in patients with mild ARDS, rising to 48% in those with severe ones.
Systemic inflammation is considered to be the main reason of ARDS. Activated neutrophils interact with the alveolar-capillary membrane causing the increasing permeability with the sequence lung edema's development. Inflammatory exudate inactivates surfactant leading to collapse and consolidation of distal airspaces with progressive loss of the lung's gas exchange surface area. Unfortunately, systemic inflammatory response syndrome (SIRS) simultaneously inhibits the mechanism of active pulmonary vasoconstriction and allows deoxygenated blood to pass through unventilated areas of the lung boosting the right-to-left shunt. Both mechanisms lead to hypoxemia, which is the main and obligatory feature of ARDS.
Actually, endothelial dysfunction and transcapillary leakage seem to be one of the main steps in the development of respiratory failure during ARDS. Last decades it was found out that glycocalyx is also participating in this process too.
Thus, it became clear that substances preserving endothelium and glycocalyx from SIRS-causing damage may have a beneficial effect in ARDS treatment. It seems to be crucially important so as the majority of drugs failed to demonstrate any positive effects in terms of ARDS treatment.
To the moment we have some evidence, which came from experimental studies, that halogenated anesthetics can preserve glycocalyx against ischemia-reperfusion injury.
The primary objective for the multicentral INVERSE Trial will be to determine the effects of inhalational (sevoflurane) versus intravenous (propofol) sedation on P/F ratio on the second day, hospital mortality and ICU (intensive care unit), and in-hospital length of stay in adults with a moderate form of ARDS.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Moscow, Russie
- Demikhov Municipal Clinical Hospital 68
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age > 18
- Endotracheal intubation or tracheostomy
- Timing: Acute onset of new or worsening of chronic respiratory symptoms within 72 hours before the randomization
- Chest imaging: Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules
- Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid overload
- Oxygenation: 100 mm Hg < PaO2/FiO2 ≤ 200 mm Hg with PEEP ≥ 5 cm H2O
Exclusion Criteria:
- History or family history of malignant hyperthermia
- History of propofol infusion syndrome
- Documented or suspected increased intracranial pressure
- Chronic restrictive pulmonary disease
- Chronic obstructive pulmonary disease
- Neuromuscular disease
- Chest wall disorder
- Pulmonary vascular disease
- NYHA class ≥ 3
- Severe pulmonary hypertension (mean pulmonary artery pressure > 40 mmHg)
- Documented ongoing COVID-19 infection
- Ongoing immunosuppressive therapy
- Previous randomization in this trial
- Post randomization exclusion criterion: Documented ongoing COVID-19 infection during the first 48 hours after the randomization
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Inhalational sedation
|
Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation |
|
Comparateur actif: Intravenous sedation
|
Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
P/F ratio
Délai: day 2 after the randomization
|
PaO2 divided on FiO2 |
day 2 after the randomization
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
28-days mortality
Délai: 28 day
|
number of deaths |
28 day
|
|
6-months mortality
Délai: 6 months
|
number of deaths |
6 months
|
|
1-year mortality
Délai: 1 year
|
number of death |
1 year
|
|
Length of stay in the intensive care unit
Délai: 1 year
|
number of days in the intensive care unit |
1 year
|
|
Length of hospitalization
Délai: 1 year
|
number of days in hospital |
1 year
|
|
Ventilator free days in ICU
Délai: 1 year
|
number of days in ICU - number of days on mechanical ventilation |
1 year
|
|
Ventilator free days during hospitalization
Délai: 1 year
|
Length of hospitalization - number of days on mechanical ventilation |
1 year
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Valery Likhvantsev, Negovsky Reanimatology Research Institute
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Maladies pulmonaires
- Troubles respiratoires
- Syndrome de détresse respiratoire
- Produits chimiques organiques
- Éthers
- Hydrocarbures
- Hydrocarbures, cyclique
- Hydrocarbures, aromatique
- Phénols
- Dérivés de benzène
- Hydrocarbures, halogénés
- Hydrocarbures, fluorés
- Éthers méthyliques
- Sévoflurane
- Propofol
Autres numéros d'identification d'étude
- INVERSE
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .